Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.45B +3.2% |
| Revenue (ttm) | 156.04M +158.9% |
| Net Income | -86.52M |
| EPS | -0.84 |
| Shares Out | 99.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,498,597 |
| Open | 25.00 |
| Previous Close | 24.39 |
| Day's Range | 24.21 - 25.48 |
| 52-Week Range | 20.23 - 38.26 |
| Beta | 2.23 |
| Analysts | Strong Buy |
| Price Target | 52.15 (+112.86%) |
| Est. Earnings | Nov 3, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price target is $52.15, which is an increase of 112.86% from the latest price.
News
Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today
20:28 EDT Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics (BEAM) today
Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today
20:28 EDT Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics (BEAM) today
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law.
Beam Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing a robust gene editing portfolio with validated base editing technology, highlighted by BEAM-302 for AATD, BEAM-304 for PKU, and risto-cel for sickle cell disease. Durable clinical results, strong safety, and a first-mover advantage position all three as potential blockbusters.
Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today
20:05 EDT Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics (BEAM) today
Beam Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026
Significant pipeline progress includes pivotal trials for AATD and sickle cell, with strong clinical data and regulatory alignment for accelerated approval. The platform enables rapid expansion to new indications, with a robust commercial and financial outlook supporting multiple blockbuster opportunities.
Beam Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Base editing platform enables precise, durable genetic corrections for multiple diseases, with recent data showing strong efficacy and safety in alpha-1 antitrypsin deficiency. Regulatory alignment supports accelerated approval, and commercial plans are advancing for sickle cell and other pipeline programs.
Beam Therapeutics falls -12.4%
Beam Therapeutics (BEAM) is down -12.4%, or -$3.67 to $25.99.
Beam Therapeutics falls -12.7%
Beam Therapeutics (BEAM) is down -12.7%, or -$3.78 to $25.88.
Beam Therapeutics Transcript: Status update
Updated BEAM-302 data show durable, functional AAT restoration and significant reduction in disease-driving Z-AAT and Z-polymers, with a favorable safety profile and strong global enrollment in the pivotal cohort. Regulatory alignment supports an accelerated approval pathway, and financial resources are robust.
Beam Therapeutics Press release: Status update
Beam Therapeutics issued a press release on September 8, 2026, disclosing material business information to investors.
Beam Therapeutics Slides: Status update
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial
Beam Therapeutics (BEAM) announced updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency, or AATD. BEAM-302 is Beam’s lead liver-targeted genetic diseas...
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Fo...
Beam Therapeutics Slides: European Respiratory Society Congress presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 7, 2026.
Beam Therapeutics appoints Eric Foster as chief commercial officer
Beam Therapeutics (BEAM) announced the appointment of Eric Foster as chief commercial officer. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product can...
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the app...
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
Beam Therapeutics price target lowered to $43 from $47 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Beam Therapeutics (BEAM) to $43 from $47 and keeps a Buy rating on the shares. The firm adjusted targets for…
Beam Therapeutics price target raised to $78 from $75 at Canaccord
Canaccord raised the firm’s price target on Beam Therapeutics (BEAM) to $78 from $75 and keeps a Buy rating on the shares. The firm updated its model and said 2Q26…
Beam Therapeutics reports Q2 EPS ($1.18), consensus ($1.13)
“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,” said John Evans, chief executive officer ...
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics Earnings release: Q2 2026
Beam Therapeutics released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Beam Therapeutics Quarterly report: Q2 2026
Beam Therapeutics has published its Q2 2026 quarterly earnings report on August 4, 2026.
Beam Therapeutics Slides: Corporate presentation
Beam Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.